I67.7 I67.8
Conditions
Interventions
Group 1: -Blood collection, HLA analysis, analysis of von willebrand factor
-Analysis of medical history and test results according to the records
Group 2: -Blood collection, HLA analysis, analysis of
Sponsors
Universitätsklinikum Essen, Institut für Transfusionsmedizin, Transplantationsdiagnostik und FuE
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria Group 1: According to the guidelines of the DGN at least three of the four criteria listed below must be met: - Clinical symptoms of multifocal or diffuse CNS disease with recurrent or progressive course. - Cerebral angiography, cerebrospinal fluid and / or MRI diagnosis-that supports the diagnosis of vasculitis. - Exclusion of an underlying systemic infection or inflammation. - Histological evidence of parenchymal or leptomeningeal vasculitis and exclusion of infection, neoplasia or other primary vascular disease. Inclusion criteria Group 2: -PCNSV as a suspected disease was not confirmed by history and examination results -Symptoms are explained by another diagnosis
Exclusion criteria
Exclusion criteria: Exclusion criteria Group 1: - Other, symptoms explanatory disease of the CNS - Severe organic brain syndrome with lack of capacity to consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the evidence or lack of an HLA association in patients with PCNSV compared to the control group. The assessment is based on laboratory results when laboratory analysis will be completed. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are differences of clinical and diagnostic findings in patients with PCNSV and patients with a different diagnosis. | — |
Countries
Germany
Contacts
Public ContactJana Becker
Alfried Krupp Krankenhaus Rüttenscheid, Klinik für Neurologie
Outcome results
None listed